Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Eur J Cancer ; 27(7): 864-6, 1991.
Article in English | MEDLINE | ID: mdl-1834118

ABSTRACT

27 patients with FIGO stage III-IV endometrial adenocarcinoma were entered in a phase II trial evaluating activity and safety of epirubicin given at 80 mg/m2 intravenously every 3 weeks. 2 complete remissions (including a pathological one) and 5 partial responses were observed for a response rate of 26% (95% confidence interval 11-46). The median time to progression and median survival for all treated patients was 6 and 9.5 months, respectively. Treatment was well tolerated. Haematological toxicity was mild. The median total cumulative dose of epirubicin was 480 mg/m2 (160-880) and cardiac toxicity was not observed. Further studies with higher doses of epirubicin in combination with other active drugs are indicated.


Subject(s)
Adenocarcinoma/drug therapy , Epirubicin/therapeutic use , Uterine Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adult , Aged , Drug Evaluation , Endometrium/pathology , Epirubicin/adverse effects , Female , Humans , Middle Aged , Neoplasm Staging , Prognosis , Uterine Neoplasms/mortality , Uterine Neoplasms/pathology , Vagina/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...